Merck KGaA to Acquire Silence Therapeutics for $1.1 Billion
Merck KGaA has agreed to acquire Silence Therapeutics, a biopharmaceutical company listed on NASDAQ under the ticker SLN, in an all-cash deal valued at approximately $1.1 billion enterprise value and around $1.3 billion equity value. The transaction will see shareholders of Silence receive $20 per American Depositary Share (ADS). This acquisition is expected to expand Merck KGaA's portfolio in innovative therapeutic solutions. The move aligns with Merck KGaA’s strategy to strengthen its position in the biopharmaceutical sector by acquiring promising companies. The all-cash structure of the deal suggests confidence from Merck KGaA and may signal a positive outlook for future growth through strategic acquisitions.
Tickers: $SLN
Topics: acquisition pharmaceuticals